Delivery Order SPE2DB25D3306-SPE2DB25FUCVC
- Not listed
- The Defense Logistics Agency (DLA) awarded a $2,859.79 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin pens under a firm fixed-price contract type. The award, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,403.84 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on August 5, 2025, with completion expected by August 6, 2025. This firm fixed-price, competitively awarded delivery order represents a routine pharmaceutical supply transaction executed without set-aside provisions. The award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $1,317.48 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Lantus SoloStar 100 Unit/ML 3ML insulin pens. This firm fixed-price contract represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of July 24, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The award falls under the company's existing Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,022.80 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of July 31, 2025. This competitively awarded, firm fixed-price contract represents a single delivery order with no set-aside designation, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's existing indefinite...
- The Defense Logistics Agency awarded a delivery order contract valued at $2,110.44 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/mL insulin pens (3mL). This competitively awarded, firm fixed-price delivery order was issued on August 8, 2025, with an ultimate completion date of August 11, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,045.60 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, non-set-aside contract employs firm fixed-price pricing and is performed at the contractor's Conshohocken, Pennsylvania location. The delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,457.49 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery transaction under AmerisourceBergen's existing pharmaceutical supply framework. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,033.47 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. The contract was competitively awarded without set-aside designation under a firm fixed-price arrangement, with performance scheduled for completion by August 18, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency for $4,292.21 to supply Lantus SoloStar 100 Unit/mL 3mL insulin pens, with completion scheduled for August 6, 2025. The award was issued on August 5, 2025, using firm fixed-price pricing with no set-aside designation, indicating competitive selection. Performance of this delivery order is based in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order falls under...
- The Defense Logistics Agency awarded a $1,227.36 delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Lantus SoloStar 100 Unit/mL insulin pens (3mL formulation). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 26, 2025, with performance to be executed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB25FUCVCDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,607.52 to supply Insulin Glargine Max SoloStar U300 3mL insulin pens. This non-set-aside, competitively awarded contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 2, 2025. The award is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 and extends through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company's performance under the larger SPE2DX contract demonstrates its capability to fulfill diverse federal medical supply needs across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, vaccines, and related medical supplies. This delivery order for insulin glargine reflects the company's ongoing role in supporting military healthcare logistics through the DLA's medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 8/29/25 |